Across TCGA pan-cancer cohorts, DEFB113 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DEFB113 data layer compared with 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher DEFB113 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB113 expression acts as an unfavorable survival marker.

COAD, LIHC, and SARC are the cancer types where DEFB113 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
LIHC	DFS	Median	All	0.038	0.556	<.001	9	view →
SARC	DFS	Median	All	0.198	0.612	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: DEFB113 tumor-vs-normal RNA expression · all DEFB113 data types